Background
==========

The secreted glycoprotein Dickkopf-related protein 3 (Dkk-3) is the most divergent member of the human Dickkopf family \[[@B1],[@B2]\] that, in contrast to other family members, does not modulate Wnt signaling \[[@B3],[@B4]\]. Dkk-3 has been proposed to represent a novel tumor suppressor since gene expression is downregulated in various tumor cells \[[@B5]-[@B9]\] and hypermethylation of its promoter correlates with cancer occurrence \[[@B10],[@B11]\].

Our previous results indicated a possible link between Dkk-3 expression and age-associated processes in the human prostate. Serial analysis of gene expression (SAGE) of human prostate basal epithelial cells revealed specific induction of *DKK3*gene during cellular senescence *in vitro*\[[@B12]\]. Moreover, Dkk-3 was found downregulated *in vivo*in prostate epithelium of patients suffering from the age-related prostatic conditions benign prostatic hyperplasia (BPH) and prostate cancer (PCa), with this downregulation counterbalanced by increased Dkk-3 protein expression in the endothelial cells of the tumor neovasculature \[[@B13]\].

This study was intended to assess changes in Dkk-3 content in prostatic fluid in these two conditions and its potential as a diagnostic marker for PCa. Since prostatic secretions constitute approximately 30% of seminal fluid volume \[[@B14]\], of all readily obtainable body fluids, ejaculate supernatant (seminal plasma; SP) reflects the contemporary status of the prostate best. We previously demonstrated that Dkk-3 could be detected in SP in apparently healthy donors at concentrations of 2.59 ± 0.41 nmol/L (range 1.62-5.25 nmol/L) that was higher that plasma Dkk-3 levels (1.22 ± 0.04 nmol/L) but much less than Dkk-3 levels found in cerebrospinal fluid (28.2 ± 1.3 nmol/L) \[[@B15]\]. SP Dkk-3 and SP prostate-specific antigen (PSA) levels were analyzed from 81 patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsies due to elevated serum PSA levels and/or abnormal digital rectal examination (DRE). Ejaculate specimens were obtained prior to biopsy. SP Dkk-3 and SP PSA levels were compared, alone and in combination with serum PSA, to the diagnostic performance of serum PSA alone to detect PCa in univariate and multivariate models.

Methods
=======

Subjects - SP samples
---------------------

Eighty-one patients who were to undergo TRUS-guided biopsies because they had an abnormal serum PSA level (\> 4 ng/mL) and/or abnormal DRE were recruited into the study from the outpatient department or from private rooms of urologists at Royal Brisbane and Women\'s Hospital (RBWH) between 1996 and 2009. Of this group, 40 men were confirmed to have cancer and 41 men had negative biopsies. Subsequently, patients with negative TRUS biopsy findings were followed with PSA and DREs and with further TRUS biopsies as indicated in selected cases to ensure the veracity of the TRUS-negative findings. A subgroup of 25 patients with negative and 21 with positive biopsy had a clinical follow-up of \> 3 years (collected between 1996 and 08/2007). This subset of patients had been selected from our archive because we were as sure as we can be that those designated not to have prostate cancer were true negatives. All SP specimens were obtained before biopsy and treatment and after giving informed consent. Patients collected ejaculate via masturbation into urine collection jars containing 20 mL of Hanks balanced salt solution in the morning at home and brought them to the hospital within 2 hours of collection (without freezing or cooling, i.e. at temperatures from \~5-25°C) where they were processed within 15 minutes after arrival. Samples were layered over 10 mL of 64% isotonic Percoll (Amersham Biosciences) and centrifuged at 2200 rpm for 30 min at 4°C. The ejaculate supernatants (SP) were removed, aliquoted and stored at -70°C until further processing (as reported previously \[[@B16],[@B17]\]). The study had the approval of the ethics committees of the RBWH and University of Queensland.

Establishment of a sensitive Dkk-3 assay
----------------------------------------

A series of six monoclonal Antibodies (mAb) INN(sbruck)-Dkk3-1 to INN-Dkk3-6 as previously described \[[@B18]\] and an affinity purified polyclonal goat anti Dkk-3 antibody (R&D Systems Cat.\#AF1118) were characterized by radioimmunoassays (RIA) according to affinity, molecular epitope localization and specificity with native (untagged) Dkk-3 and the commercially available homologous proteins Dkk-1, Dkk-4 and Sgy-1 (R&D Systems) as described elsewhere \[[@B18]\]. The antibodies with the highest affinity towards Dkk-3 (mAb INN-Dkk3-1 and the goat polyclonal antibody) showed no significant reactions towards the homologous proteins Dkk-1 and Dkk-4 however the polyclonal antibody when tested at a concentration of 5 μg/mL reacted slightly with the homologous protein Sgy-1 (Figure [1A](#F1){ref-type="fig"}). In competitive RIA to assess cross-reactivity increasing concentrations of Dkk-3 or Sgy-1 competed with ^125^I labeled Dkk-3 (approximately 25,000 cpm) for binding to 30 ng of polyclonal goat anti Dkk-3 antibody in 300 μL total reaction volume (1% BSA/PBS) overnight at 4°C. Separation of bound from free tracer was performed as described \[[@B18]\], and cross-reactivity towards Sgy-1 was determined to be 0.025% (Figure [1B](#F1){ref-type="fig"}). Epitope mapping by polypeptide screening revealed localization of the INN-Dkk3-1 epitope in the N-terminal region (aminoacids 21-147) while the polyclonal antibody predominantly reacted with the C-terminal region (aminoacids 200-350; data not shown).

![**Establishment of the Dkk-3 assay**. mAb INN-Dkk3-1 and goat polyclonal antibody (R&D Systems) showed no significant cross-reactivities with homologous proteins Dkk-1 and Dkk-4. The polyclonal antibody (5 μg/mL) showed weak reactivity for the homologous protein Sgy-1 in a direct binding RIA (A). In a competitive RIA the goat polyclonal antibody showed a cross-reactivity (XR) of 0.025% for Sgy-1 (B). A standard curve from 0.25 pmol/L - 250 pmol/L Dkk-3 in comparison to the homologous proteins at a concentration of 1000 pmol/L revealed cross-reactivities in the sandwich assay of \< 0.01% (C). The established sandwich assay had a recovery of 92% and sensitivity of 1 pmol/L. The intra- and inter-assay variances (%CV) at a protein concentration of 40 pmol/L were 11% and 13%, respectively.](1479-5876-9-193-1){#F1}

A sensitive sandwich immunoradiometric assay (IRMA) was established with mAb INN-Dkk3-1 (coating antibody) and the ^125^l labeled goat polyclonal antibody (R&D Systems) as described previously \[[@B19]\]. All samples were run in duplicate and results calculated from specific mean signal (mean - zero standard). Native i.e. untagged Dkk-3 purified via HPLC (anion exchange followed by size exclusion chromatography) from conditioned media of stably transfected LNCaP cells \[[@B13]\] was used as standard. Cross-reactivity was shown to be \< 0.1% for Sgy-1 and \< 0.01% for Dkk-1 and Dkk-4 (Figure [1C](#F1){ref-type="fig"}).

To increase sensitivity and to allow higher sample throughput, the assay was commuted to a 96-well plate based indirect immunoenzymometric assay (IEMA) described previously \[[@B18]\] by replacement of the ^125^l labeled antibody by a biotinylated variant of the polyclonal goat anti Dkk-3 antibody (R&D Systems Cat.\#BAF1118). All samples were run in duplicate and results were calculated from specific mean signal (mean - zero standard). Recovery was 92% and sensitivity 1 pmol/L. The intra- and inter-assay variances (%CV) at a protein concentration of 40 pmol/L were 11% and 13%, respectively.

PSA and total protein measurements
----------------------------------

Serum PSA was assayed using a fluoroimmunoenzymetric two-site assay (Medics 1200 Dx AIA, Tosoh Corp.). SP PSA values were analyzed by the ADVIA Centaur PSA assay (Siemens Healthcare Diagnostics) at a dilution of 1:5000. SP Dkk-3 and PSA levels were normalized to total protein levels determined by the Pierce BCA Protein Assay Kit (Thermo Scientific).

Statistical analyses
--------------------

Assay sensitivity was defined as the mean signal of non-specific binding (NSB = zero standard) plus three standard deviations (NSB + 3SD). Percent coefficient of variation (%CV) was used as a measure of dispersion about the mean and expressed SD as a percentage of the mean.

Statistical differences among groups were calculated by Mann-Whitney test. Multivariate logistic regression was used to analyze correlations between investigated markers and PCa diagnostic status and the quality of the obtained models were estimated by Hosmer-Lemeshow goodness-of-fit tests. The diagnostic performance of the tested variables and the multivariate models was evaluated by plotting the receiver-operating characteristics (ROC) curve and calculating the area under the ROC curve (AUC). Associations between the investigated markers, age at time of the ejaculation specimen and Gleason score were evaluated using Pearson correlation analysis or Spearman\'s rank correlation analysis when data belonged to categorial variables.

All statistical analyses were performed using PASW Statistics 18 (IBM).

Results
=======

The characteristics of all 81 patients and the 46 patients with a follow-up of \> 3 years are summarized in Table [1](#T1){ref-type="table"}. Serum PSA as well as SP Dkk-3 levels (characteristics of the sandwich assay depicted in Figure [1](#F1){ref-type="fig"}) were found significantly higher in the PCa confirmed patients in both, the all patients cohort as well as the \> 3 year follow-up subgroup. SP PSA levels were although also slightly elevated not significantly different. A multivariate logistic regression model based on serum PSA and SP Dkk-3 levels (model A) significantly discriminated negative from positive biopsies in both cohorts (Table [2](#T2){ref-type="table"}; all patients: *p*= 0.007, predictive accuracy = 64.2%; follow-up \> 3 years: *p*= 0.007, predictive accuracy = 73.9). Although not significantly different between patients with positive and negative biopsies, inclusion of SP PSA (model B) increased the predictive accuracy of the model for the cohort of all patients.

###### 

Characteristics of the study cohort.

  all patients                                                             
  ---------------------------- --------------------- --------------------- --------------
  **Characteristic**           **Negative biopsy**   **Positive biopsy**   ***p*value**
                                                                           
  **Patients, N**              **41**                **40**                
  Age\*, yr                                                                0.981
   Mean ± SEM                  61.0 ± 1.3            61.5 ± 1.3            
   Median (IQR)                62.5 (57.1 - 67.0)    61.9 (55.6 - 66.6)    
  serum PSA \[ng/mL\]                                                      0.026
   Mean ± SEM                  7.5 ± 1.0             11.6 ± 1.9            
   Median (IQR)                6.2 (4.1 - 8.9)       7.3 (5.8 - 13.3)      
  SP Dkk-3 \[fmol/mg\]\*\*                                                 0.039
   Mean ± SEM                  69.2 ± 9.4            100.9 ± 12.3          
   Median (IQR)                55.7 (35.8 - 91.2)    74.5 (41.7 - 124.5)   
  SP PSA \[μg/mg\]\*\*                                                     0.317
   Mean ± SEM                  23.8 ± 3.3            28.0 ± 3.5            
   Median (IQR)                16.8 (8.1 - 35.9)     19.9 (10.8 - 42.5)    
  Biopsy Gleason score                                                     
   ≤ 6                                               6                     
   7                                                 26                    
   ≥ 8                                               8                     
                                                                           
  clinical follow-up \> 3 yr                                               
                                                                           
  Characteristic               Negative biopsy       Positive biopsy       *p*value
                                                                           
  Patients, N                  25                    21                    
  Age\*, yr                                                                0.700
   Mean ± SEM                  63.1 ± 1.6            61.6 ± 2.3            
   Median (IQR)                64.0 (60.9 - 68.9)    60.5 (53.7 - 69.8)    
  serum PSA \[ng/mL\]                                                      0.012
   Mean ± SEM                  8.0 ± 1.6             14.3 ± 3.3            
   Median (IQR)                6.2 (3.6 - 10.4)      9.2 (6.5 - 16.0)      
  SP Dkk-3 \[fmol/mg\]\*\*                                                 0.027
   Mean ± SEM                  56.3 ± 8.4            100.0 ± 16.6          
   Median (IQR)                49.6 (22.3 - 76.4)    76.3 (35.9 - 169.4)   
  SP PSA \[μg/mg\]\*\*                                                     0.474
   Mean ± SEM                  23.4 ± 4.5            27.4 ± 5.1            
   Median (IQR)                16.8 (7.3 - 40.1)     19.5 (12.7 - 35.0)    
  Biopsy Gleason score                                                     
   ≤ 6                                               3                     
   7                                                 14                    
   ≥ 8                                               4                     

SEM, standard error of the mean; IQR, interquartile range; PSA, prostate-specific antigen; SP, seminal plasma; \* at time of ejaculate specimen; \*\* per total protein; *p*values determined by Mann-Whitney test.

###### 

Multivariate logistic regression analyses to asses the predictive value in prostate cancer detection.

  Cohort                       Variable     β-coefficient   OR      95% CI          *p*-value   Predictive accuracy %   H-L *p*-value
  ---------------------------- ------------ --------------- ------- --------------- ----------- ----------------------- ---------------
  all patients                 model A                                              0.007       64.2                    0.979
                                serum PSA   0.071           1.074   0.997 - 1.157   0.06                                
                                SP Dkk-3    0.008           1.008   1.000 - 1.016   0.039                               
                               model B                                              0.007       69.1                    0.737
                                serum PSA   0.07            1.072   0.996 - 1.002   0.063                               
                                SP Dkk-3    0.01            1.010   1.002 - 1.018   0.019                               
                                SP PSA      0.017           1.018   0.995 - 1.041   0.13                                
  clinical follow-up \> 3 yr   model A                                              0.005       73.9                    0.691
                                serum PSA   0.071           1.074   0.992 - 1.164   0.08                                
                                SP Dkk-3    0.014           1.015   1.002 - 1.027   0.02                                
                               model B                                              0.007       73.9                    0.806
                                serum PSA   0.069           1.072   0.991 - 1.159   0.083                               
                                SP Dkk-3    0.016           1.016   1.004 - 1.029   0.012                               
                                SP PSA      0.018           1.018   0.988 - 1.049   0.238                               

OR, odds ration; CI, confidence intervall; H-L, Hosmer-Lemeshow test; PSA, prostate-specific antigen; SP, seminal plasma.

The diagnostic performances of the univariate test variables and the multivariate models were determined by ROC analyses (Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}). AUCs, as a measure for diagnostic accuracy, for serum PSA, SP Dkk-3, SP PSA, model A and model B were 0.644, 0.633, 0.565, 0.658 and 0.710 in the cohort of all patients and 0.696, 0.667, 0.562, 0.724 and 0.777 in patients with \> 3 years clinical follow-up, respectively, showing that the multiplex models had higher AUCs in both cohorts compared with the single markers and model B higher accuracy compared with model A. Moreover, except for SP PSA all AUCs where higher in the \> 3 year follow-up cohort.

![**Receiver operator characteristics (ROC) curves**. ROC curves of serum prostate-specific antigen (PSA), seminal plasma (SP) Dkk-3 and SP PSA levels and the multivariate models based on serum PSA and SP Dkk-3 (model A) or on all three individual markers (model B) for (A) the entire cohort and (B) patients with \> 3 years clinical follow-up.](1479-5876-9-193-2){#F2}

###### 

Determination of diagnostic accuracy.

              all patients   clinical follow-up \> 3 yr           
  ----------- -------------- ---------------------------- ------- ---------------
  serum PSA   0.644          0.524 - 0.763                0.696   0.544 - 0.848
  SP Dkk-3    0.633          0.512 - 0.754                0.667   0.509 - 0.825
  SP PSA      0.565          0.439 - 0.690                0.562   0.394 - 0.730
  model A     0.658          0.539 - 0.776                0.724   0.568 - 0.880
  model B     0.710          0.597 - 0.824                0.777   0.638 - 0.917

Areas under the receiver operator characteristics curve for univariate test variables and multivariate models.

AUC, area under the curve; CI confidence intervall; PSA, prostate-specific antigen; SP, seminal plasma.

Lastly, correlations between the individual markers, age and biopsy Gleason score were analyzed (Table [4](#T4){ref-type="table"}). SP Dkk-3 and SP PSA were found independent for serum PSA, Age and Gleason score whereas serum PSA levels correlated with Gleason score (all patients: *p*= 0.034; \> 3 years follow-up: *p*= 0.024) but not with age. Interestingly SP Dkk-3 levels correlated with SP PSA levels (all patients: *p*= 0.013) but this correlation was limited to patients with biopsy confirmed PCa (all patients: *p*= 0.007; \> 3 years follow-up: *p*= 0.026) while no correlation was observed in patients with negative biopsies (all patients: *p*= 0.301; \> 3 years follow-up: *p*= 0.620).

###### 

Correlative associations between univariate test variables.

                                   SP PSA    serum PSA   Age       Gleason\*                                                     
  -------------------- ----------- --------- ----------- --------- ----------- --------- --------- --------- --------- --------- ---------
  all patients         SP Dkk-3    -0.276    -0.165      -0.417    -0.950      -0.212    -0.128    0.118     -0.010    0.220     0.019
                                   (0.013)   (0.301)     (0.007)   (0.400)     (0.183)   (0.432)   (0.294)   (0.950)   (0.173)   (0.906)
                       SP PSA      1         1           1         0.020       0.125     -0.068    -0.320    -0.107    0.037     0.114
                                                                   (0.860)     (0.437)   (0.679)   (0.777)   (0.507)   (0.822)   (0.483)
                       serum PSA   0.020     0.125       -0.038    1           1         1         0.117     -0.107    0.024     0.336
                                   (0.860)   (0.437)     (0.679)                                   (0.298)   (0.507)   (0.884)   (0.034)
  clinical follow-up   SP Dkk-3    -0.241    -0.104      -0.430    -0.100      -0.327    -0.174    0.080     -0.307    0.336     0.123
   \> 3 yr                         (0.054)   (0.620)     (0.026)   (0.506)     (0.111)   (0.450)   (0.596)   (0.135)   (0.137)   (0.595)
                       SP PSA      1         1           1         0.043       0.219     -0.099    0.099     0.071     0.169     0.181
                                                                   (0.777)     (0.293)   (0.668)   (0.511)   (0.844)   (0.465)   (0.431)
                       serum PSA   -0.100    0.219       -0.099    1           1         1         0.085     0.312     0.018     0.491
                                   (0.506)   (0.293)     (0.668)                                   (0.572)   (0.129)   (0.938)   (0.024)

SP, seminal plasma; PSA, prostate-specific antigen; neg, negative biopsy; pos, positive biopsy; r, correlation coefficient.

Correlations were calculated by Pearson correlation analysis except for \*Spearman\'s rank correlation analysis.

Discussion
==========

Serum PSA is currently the most widely used PCa screening test, however, PSA is organ- but not disease-specific, thus its value to predict PCa is limited and there is a need for additional disease markers. We consider SP as an ideal source to monitor pathological changes in the prostate since it more directly reflects local glandular production than other sources such as peripheral blood. Moreover, SP donation is completely non-invasive avoiding the discomfort and possible concerns associated with prostate massage necessary to obtain post-massage urine. Previously, we reported that the inactive free:total PSA ratios in SP from men with suspected PCa did not distinguish between those harboring malignant as opposed to benign disease \[[@B16]\]. The present study was designed to assess changes in Dkk-3 levels in SP and its potential for discriminating benign from malignant prostatic conditions in patients who were to undergo TRUS-guided biopsy due to elevated serum PSA (\> 4 ng/mL) and/or abnormal DRE.

With the IEMA developed in our laboratory, SP Dkk-3 levels were found significantly higher in patients with biopsy confirmed PCa (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg). Of note, this difference was more pronounced in the subgroup of patients with a clinical follow-up of \> 3 years (100.0 ± 16.6 vs. 56.3 ± 8.4 fmol/mg) for whom, as a consequence, there was greater veracity for the negative biopsy finding to be correct (Table [1](#T1){ref-type="table"}).

While Dkk-3 levels as a single marker distinguished between prostate cancer and non-cancer on the basis of TRUS biopsies in the study cohort with a similar diagnostic accuracy compared with serum PSA (SP Dkk-3: AUC = 0.633; serum PSA: AUC = 0.644), the diagnostic accuracy of SP Dkk-3 levels was enhanced in multivariate models including serum PSA (model A) and both, serum and SP PSA levels (model B). Neither SP Dkk-3 nor SP PSA levels correlated with biopsy Gleason scores. However, this might be in part due to the patient cohort characteristics with approximately 2/3 of all positive biopsies reported as Gleason 7 (either Gleason 3+4 or Gleason 4+3). Of interest SP Dkk-3 negatively correlated with SP PSA levels in the positive biopsy cohorts, which might be responsible for the higher accuracy of model B compared with model A.

The biological significance of the increase in SP Dkk-3 levels in patients with positive vs. negative PCa biopsy findings remains unclear. As expression of Dkk-3 in secretory epithelial cells of the prostate is reduced in both PCa \[[@B5],[@B13],[@B20]\] and BPH \[[@B13]\], one might have expected a similar effect on SP Dkk-3 levels in patients with both these conditions. However, it is conceivable that the elevated Dkk-3 levels in PCa SP are derived from the tumor neovasculature, where high levels of Dkk-3 are produced \[[@B13]\]. Elevated serum PSA levels in PCa patients are supposed to be primarily an effect of tissue degradation and thus increased tissue permeability while in normal/BPH tissue an intact basement membrane prevents leakage \[[@B21]\]. Likewise, Dkk-3 as a secreted protein of similar size (PSA protein backbone: 237 aminoacids; Dkk-3 protein backbone: 329 aminoacids) might be able to diffuse through the disorganized PCa tissue.

Due to the limited number of SP samples available, especially from patients with long-term follow-up, it was not useful to further stratify the biopsy confirmed PCa patients according to their risk in order to more closely investigate the SP Dkk-3 and SP PSA correlation within this cohort.

Given the limited diagnostic accuracy of single markers including PSA, much effort has been made to identify potential additional PCa markers from different sources including SP \[[@B22]-[@B24]\]. Our data demonstrate that SP is a valuable and valid source for biomarkers of prostatic disease. The most promising attempt to improve PCa diagnosis appears the establishment of a set of individual biomarkers. Thus, SP Dkk-3 should be considered in a panel of markers such as prostate cancer antigen 3 (PCA3) and/or hepsin \[[@B25]\] to be evaluated in combination in future validation studies.

Conclusions
===========

A newly established sensitive and specific IEMA for Dkk-3 revealed significantly higher SP Dkk-3 levels in men with biopsy confirmed PCa indicating its inclusion in a PCa diagnostic marker panel. A multivariate model based on SP Dkk-3 and serum PSA levels showed higher diagnostic accuracy compared with the individual markers. Although mean SP PSA levels were not significantly altered in PCa patients, a combination of all three markers further improved results with the multivariate model, indicating potential utility in determining and integrating all three in a panel of biomarkers. However, more research is necessary to validate that SP Dkk-3 represents a clinically applicable PCa biomarker, ideally in a set of individual biomarkers.
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